LJPC La Jolla Pharmaceutical Company gains 17% Feb 12, 2021

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.http://www.priceseries.com/trade/LJPC-La-Jolla-Pharmaceutical-Company-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021012520210212.html